BioDelivery Sciences International
CompanyUnited States
BioDelivery Sciences International develops one asset, approved (celecoxib in acute pain). Mostly small molecule acting on inflammation, PTGS2 and OPRM1; based in the United States.
- 1
- Asset
- Furthest
- Approved
- 3
- Trials
- 0
- Signals
Pipeline
1Selective cyclooxygenase-2 inhibitor reducing prostaglandin synthesis to relieve pain and inflammation
Approved, Small molecule, Inflammation, PTGS2, acute pain, adenomatous polyposis coli
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials3
- Similar companies6
Updated 10 Oct 2026 · 59 sources